Prostate Cancer - Pipeline Review, H1 2020

May 2020 | 2967 pages | ID: PA6A3B09973EN
Global Markets Direct

Abstracts

Prostate Cancer - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prostate Cancer – Pipeline Review, H1 2020, provides an overview of the Prostate Cancer (Oncology) pipeline landscape.

Prostate cancer is a form of cancer that affects men and starts off in the prostate gland. Prostate cancer usually occurs in older men. Symptoms include trouble urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips or thighs, bone pain and erectile dysfunction. Predisposing factors include age, family history and obesity. Treatment includes surgery, chemotherapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prostate Cancer – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 19, 169, 130, 1, 15, 264, 49 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 12, 17, 1, 69 and 26 molecules, respectively.

Prostate Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Prostate Cancer (Oncology).
• The pipeline guide reviews pipeline therapeutics for Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Prostate Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Prostate Cancer (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Prostate Cancer (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Prostate Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Prostate Cancer - Overview
Prostate Cancer - Therapeutics Development
Prostate Cancer - Therapeutics Assessment
Prostate Cancer - Companies Involved in Therapeutics Development
Prostate Cancer - Drug Profiles
Prostate Cancer - Dormant Projects
Prostate Cancer - Discontinued Products
Prostate Cancer - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Prostate Cancer, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Number of Products by Stage and Molecule Type, H1 2020 (Contd..1), H1 2020
Prostate Cancer - Pipeline by 4D Pharma Plc, H1 2020
Prostate Cancer - Pipeline by 4SC AG, H1 2020
Prostate Cancer - Pipeline by AB Science SA, H1 2020
Prostate Cancer - Pipeline by Abbisko Therapeutics Co Ltd, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Prostate Cancer, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

4D Pharma Plc
4SC AG
AB Science SA
Abbisko Therapeutics Co Ltd
AbbVie Inc
Abion Inc
Actinium Pharmaceuticals Inc
ADC Therapeutics SA
Adicet Bio Inc
Aduro BioTech Inc
Advanced Accelerator Applications SA
Advanced Cancer Therapeutics LLC
Advaxis Inc
Adze Biotechnology Inc
Aeglea BioTherapeutics Inc
Affina Biotechnologies Inc
Agenus Inc
AIM ImmunoTech Inc
Akshaya Bio Inc
Alla Chem LLC
Allife Medical Science and Technology Co Ltd
Alligator Bioscience AB
Almac Discovery Ltd
AlphaMab Co Ltd
Alphamab Oncology
ALRISE Biosystems GmbH
Altay Therapeutics Inc
Altum Pharmaceuticals Inc
Ambrx Inc
American Gene Technologies International Inc
Amgen Inc
Anastasis Biotec Ltd
Anavex Life Sciences Corp
Andes Biotechnologies
Anew Oncology Inc
AnGes Inc
AntiCancer Inc
Antikor Biopharma Ltd
Apcure SAS
Apexian Pharmaceuticals Inc
Aphios Corp
Apidel SA
APIM Therapeutics AS
Aqualung Therapeutics Corp
Aranda Pharma Ltd
Arcus Biosciences Inc
Arrien Pharmaceuticals LLC
Artelo Biosciences Inc
Arvinas Inc
Ascelia Pharma AB
Asdera LLC
Asieris Pharmaceuticals Co Ltd
AskAt Inc
AstraZeneca Plc
Athenex Inc
AUM Biosciences Pte Ltd
Auransa Inc
Aurigene Discovery Technologies Ltd
Autolus Therapeutics Plc
Avican Inc
Avivia BV
B3 Bio Inc
Bantam Pharmaceutical LLC
Basilea Pharmaceutica Ltd
Bavarian Nordic A/S
Bayer AG
BeiGene Ltd
Bellicum Pharmaceuticals Inc
Bexion Pharmaceuticals LLC
BeyondSpring Inc
Bio-Cancer Treatment International Ltd
BioAtla LLC
BioCurity Pharmaceuticals Inc
BioEclipse Therapeutics Inc
Biokine Therapeutics Ltd
BioNTech SE
Biopep Solutions Inc
Biosceptre International Ltd
Biosion Inc
BioVec Pharma Inc
Bioven Group
BioXcel Therapeutics Inc
bluebird bio Inc
Boehringer Ingelheim International GmbH
BriaCell Therapeutics Corp
Bristol-Myers Squibb Co
Bukwang Pharm Co Ltd
Calidi Biotherapeutics Inc
Calidum Inc
Camurus AB
Can-Fite BioPharma Ltd
CanBas Co Ltd
Cancer Targeted Technology LLC
Candel Therapeutics
Canget BioTekpharma LLC
Cantex Pharmaceuticals Inc
Cardiff Oncology Inc
Carrick Therapeutics UK Ltd
CAS-Lamvac Biotech Co Ltd
Cassiopea SpA
Cellbion Co Ltd
CellCentric Ltd
Celldex Therapeutics Inc
Cellestia Biotech AG
Cellid Co Ltd
Cellmid Ltd
Cello Therapeutics Inc
Cells for Cells SA
Cellular Biomedicine Group Inc
Celprogen Inc
Celtek Bioscience LLC
CG Oncology Inc
ChemRegen Inc
Chong Kun Dang Pharmaceutical Corp
Clarity Pharmaceuticals Pty Ltd
Cloaked Therapeutics LLC
Clovis Oncology Inc
CMG Pharmaceutical Co Ltd
Codagenix Inc
CohBar Inc
Constellation Pharmaceuticals Inc
Context Therapeutics LLC
Convalife
Corcept Therapeutics Inc
Corvus Pharmaceuticals Inc
Crescendo Biologics Ltd
Cue Biopharma Inc
Curadis GmbH
CureLab Oncology Inc
CureMeta LLC
Cytodyn Inc
CytoMed Therapeutics Pte Ltd
CytomX Therapeutics Inc
CytoVac AS
CZ BioMed Corp
Daewon Pharmaceutical Co Ltd
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Debiopharm International SA
Deciphera Pharmaceuticals Inc
DEKK-TEC Inc
DevaCell Inc
DexTech Medical AB
Diakonos Research Ltd
Diffusion Pharmaceuticals Inc
DisperSol Technologies LLC
Disulfican Ltd
DNJ Pharma Inc
Druggability Technologies Holdings Ltd
eFFECTOR Therapeutics Inc
Eli Lilly and Co
Ellipses Pharma Ltd
Emtora Biosciences
Enceladus Pharmaceuticals BV
EndoCeutics Inc
Endocyte Inc
EntreChem SL
EOS Biosciences Inc
Epigene Therapeutics Inc
Epizyme Inc
Errant Gene Therapeutics LLC
Ervaxx Ltd
Esanex Inc
Esperance Pharmaceuticals Inc
ESSA Pharma Inc
EstryX Pharma Ltd
Etubics Corp
Eurofarma Laboratorios SA
Evgen Pharma Plc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Felicitex Therapeutics Inc
Ferring International Center SA
For-Robin Inc
Foresee Pharmaceuticals Co Ltd
Forma Therapeutics Inc
Fortis Therapeutics Inc
Fujifilm Holdings Corp
Fusion Antibodies Plc
G1 Therapeutics Inc
Galectin Therapeutics Inc
GEMoaB Monoclonals GmbH
GemVax & KAEL Co Ltd
Gene Sciences Inc
Genelux Corp
Genentech Inc
Geneos Therapeutics Inc
GeneScience Pharmaceuticals Co Ltd
Genetic Immunity Inc
GenKyoTex SA
Genmab AS
GeoVax Labs Inc
Gibson Oncology LLC
Gilead Sciences Inc
Glactone Pharma AB
GlaxoSmithKline Plc
GLG Pharma SA
Glycomantra Inc
GlycoMimetics Inc
GlycoNex Inc
GlyTech Inc
GlyTherix Ltd
Gossamer Bio Inc
GP Pharm SA
Guangzhou Anjie Biomedical Technology Co Ltd
Hanmi Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Harpoon Therapeutics Inc
Health Ever Bio-Tech Co Ltd
Heidelberg Pharma AG
Helixmith Co Ltd